---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-032650"
form_type: "8-K"
ticker: "PDSB"
cik: "0001472091"
company_name: "PDS Biotechnology Corp"
filed_at: "2026-08-13T12:35:22+00:00"
generated_at: "2026-08-13T12:40:08.417030+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# PDS Biotech refocuses on PDS0301, discontinues PDS0101 Phase 3 trial; Q2 net loss $9.8M

## Summary
- Q2 2026 net loss $9.8M ($0.18/share) vs $9.4M ($0.21) year-ago; cash $5.6M at June 30.
- Strategic refocus: PDS0301 (IL-12 immunocytokine) becomes lead program; PDS0101 VERSATILE-003 Phase 3 trial discontinued.
- Positive mCRC data: ORR 77.8% (7/9) with PDS0301 vs 35% (7/20) without; 24-month survival ~80% vs ~35%.
- Company to pursue partnerships for PDS0101 development; R&D expenses down to $3.3M from $4.2M.

## SEC filing metadata
- accession: 0001140361-26-032650
- form_type: 8-K
- ticker: PDSB
- cik: 0001472091
- company_name: PDS Biotechnology Corp
- filed_at: 2026-08-13T12:35:22+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1472091/000114036126032650/0001140361-26-032650-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1472091/000114036126032650/ef20080122_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-032650
- JSON: https://secwatch.observer/filing/0001140361-26-032650.json
- Plain text: https://secwatch.observer/filing/0001140361-26-032650.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.